Waters Stock News

Headlines: Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1 Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between empty, partial, full, and overfull viral vector capsids in less than 10 minutes per sample.2 Decreases sample volumes by 100 times vs. current methods for a...

MILFORD, Mass. , Oct. 1, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q3 2025 financial results conference call on Tuesday, November 4th, 2025 at 8:00 a.m.

Waters Corporation (NYSE:WAT ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 9:30 AM EDT Company Participants Udit Batra - President, CEO & Director Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst Let's start. Thanks, everybody, for sticking with us.

MILFORD, Mass. , Aug. 26, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.

Waters Corporation (NYSE:WAT ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Amol Chaubal - Senior VP & CFO Caspar Tudor - Head of Investor Relations Udit Batra - President, CEO & Director Conference Call Participants Catherine Walden Ramsey Schulte - Robert W. Baird & Co. Incorporated, Research Division Daniel Gregory Brennan - TD Cowen, Research Division Jack...

Waters (WAT) Q2 Revenue Jumps 9%

Highlights Sales of $771 million exceeded guidance range; grew 9% as reported and 8% in constant currency GAAP EPS of $2.47 and non-GAAP EPS of $2.95, above mid-point of guidance range Instruments grew mid-single-digits in constant currency, led by high-single-digit LC and MS growth – with continued strength in instrument replacement, particularly among large pharma and CDMO customers Recurring...

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Waters Corporation (NYSE: WAT) and Becton, Dickinson and Company's (NYSE: BDX) Biosciences & Diagnostic Solutions business. Upon completion of the proposed transaction, existing Waters shareholde...